Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Change in Cash: 2020-2025

Historic Change in Cash for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $53.9 million.

  • Mirum Pharmaceuticals' Change in Cash rose 633.60% to $53.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.1 million, marking a year-over-year increase of 174.19%. This contributed to the annual value of -$63.4 million for FY2024, which is 140.04% down from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Change in Cash is $53.9 million, which was up 229.56% from $16.4 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Change in Cash high stood at $147.8 million for Q2 2023, and its period low was -$69.3 million during Q2 2024.
  • Over the past 3 years, Mirum Pharmaceuticals' median Change in Cash value was $5.8 million (recorded in 2023), while the average stood at $14.0 million.
  • Its Change in Cash has fluctuated over the past 5 years, first spiked by 1,543.05% in 2023, then tumbled by 273.23% in 2024.
  • Mirum Pharmaceuticals' Change in Cash (Quarterly) stood at $75.5 million in 2021, then plummeted by 110.27% to -$7.8 million in 2022, then plummeted by 115.74% to -$16.7 million in 2023, then spiked by 97.22% to -$466,000 in 2024, then surged by 633.60% to $53.9 million in 2025.
  • Its last three reported values are $53.9 million in Q3 2025, $16.4 million for Q2 2025, and -$10.7 million during Q1 2025.